University of Maryland Company Trauma Solutions Named Finalist in $250K Draper Fisher Jurvetson and Cisco Systems Global Business Plan C...( COLLEGE PARK Md. June 25 -- Trauma S...),Health

COLLEGE PARK, Md., June 25 /PRNewswire-USNewswire/ -- Trauma Solutions, a company developing the first and only synthetic, hemostatic material capable of simultaneously inducing blood clotting and delivering therapeutics, has been named a finalist in the $250K Draper Fisher Jurvetson and Cisco Systems Global Business Plan Competition.

The company, founded by graduate research assistant Brendan Casey and Keystone Professor Peter Kofinas, both from the Fischell Department of Bioengineering, along with Adam Behrens, an undergraduate research assistant from the Department of Chemical and Biomolecular Engineering, is one of 16 finalists from fifteen different schools in six countries. Finalists were selected from thousands of eligible business plans in nine countries across the globe.

Trauma Solutions, formerly called Haemechanics, took first place and $20K in the University of Maryland $75K Business Plan Competition in the life sciences division on May 8.

"We are very excited to be selected as finalists for this prestigious international business plan competition," says Kofinas. "This will result in higher visibility for our hemostatic product and an opportunity to network with one of the nation's premier venture capital firms and a technology industry leader. We are grateful to Jim Chung, director of the Mtech VentureAccelerator program, for his help and coaching."

Trauma Solutions' hemostatic (stops bleeding) material is able to induce clotting as effectively as biologically based products at a fraction of the price. Its capability to simultaneously deliver therapeutics in a regulated manner makes it completely unique to the market and in line with the specific demands of commercial, next generation hemostatics and military-grade blood coagulation materials for use on the battlefield. Trauma Solutions was founded to develop an advanced line of hemostatic products based on this mater
'/>"/>